These include development and exacerbation of other autoimmune diseases (thyroiditis, immune thrombocytopenia, and anemia), capillary leak syndrome, anaphylactic shock and polyneuropathy.1 There are also reports of livedoreticularis and Raynaud phenomenon, renal thrombotic microangiopathy and malignant arterial hypertension in patients with MS receiving IFN-β treatment.2 This evidence concerns the gene IFNB1 and myeloid sarcoma.